163 related articles for article (PubMed ID: 37585496)
61. Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.
Turner TH; Alzubi MA; Sohal SS; Olex AL; Dozmorov MG; Harrell JC
Breast Cancer Res Treat; 2018 Jul; 170(2):221-234. PubMed ID: 29532339
[TBL] [Abstract][Full Text] [Related]
62. Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor.
Khalighfard S; Alizadeh AM; Poorkhani A; Motahari M; Tahmasebifar A; Omranipour R; Keshavarz P; Haddad P
Eur J Pharmacol; 2020 Dec; 889():173605. PubMed ID: 32980347
[TBL] [Abstract][Full Text] [Related]
63. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
64. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
65. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X; Bai Y; Rabbie S; Kim DW; Ahn MJ; Yang JC; Zhang X
Sci Transl Med; 2016 Dec; 8(368):368ra172. PubMed ID: 27928026
[TBL] [Abstract][Full Text] [Related]
66. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
Gilardini Montani MS; Prodosmo A; Stagni V; Merli D; Monteonofrio L; Gatti V; Gentileschi MP; Barilà D; Soddu S
J Exp Clin Cancer Res; 2013 Nov; 32(1):95. PubMed ID: 24252502
[TBL] [Abstract][Full Text] [Related]
67. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
[TBL] [Abstract][Full Text] [Related]
68. Sodium glycididazole enhances the radiosensitivity of laryngeal cancer cells through downregulation of ATM signaling pathway.
Zeng YC; Xing R; Zeng J; Xue M; Chi F; Xin Y; Fan GL; Wang HM; Duan QY; Sun YN; Niu N; Wu R
Tumour Biol; 2016 May; 37(5):5869-78. PubMed ID: 26586399
[TBL] [Abstract][Full Text] [Related]
69. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.
Golding SE; Rosenberg E; Valerie N; Hussaini I; Frigerio M; Cockcroft XF; Chong WY; Hummersone M; Rigoreau L; Menear KA; O'Connor MJ; Povirk LF; van Meter T; Valerie K
Mol Cancer Ther; 2009 Oct; 8(10):2894-902. PubMed ID: 19808981
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
71. Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response.
Min A; Jang H; Kim S; Lee KH; Kim DK; Suh KJ; Yang Y; Elvin P; O'Connor MJ; Im SA
Mol Cancer Ther; 2018 Dec; 17(12):2507-2518. PubMed ID: 30232143
[TBL] [Abstract][Full Text] [Related]
72. TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.
Bouquet F; Pal A; Pilones KA; Demaria S; Hann B; Akhurst RJ; Babb JS; Lonning SM; DeWyngaert JK; Formenti SC; Barcellos-Hoff MH
Clin Cancer Res; 2011 Nov; 17(21):6754-65. PubMed ID: 22028490
[TBL] [Abstract][Full Text] [Related]
73. Inhibition of DNA‑PK activity sensitizes A549 cells to X‑ray irradiation by inducing the ATM‑dependent DNA damage response.
Yang L; Yang X; Tang Y; Zhang D; Zhu L; Wang S; Wang B; Ma T
Mol Med Rep; 2018 Jun; 17(6):7545-7552. PubMed ID: 29620203
[TBL] [Abstract][Full Text] [Related]
74. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
75. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
[TBL] [Abstract][Full Text] [Related]
76. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
[TBL] [Abstract][Full Text] [Related]
77. Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target.
Grellety T; Callens C; Richard E; Briaux A; Vélasco V; Pulido M; Gonçalves A; Gestraud P; MacGrogan G; Bonnefoi H; Cardinaud B
Clin Cancer Res; 2019 Jan; 25(2):856-867. PubMed ID: 30352905
[TBL] [Abstract][Full Text] [Related]
78. Mangiferin induces radiosensitization in glioblastoma cells by inhibiting nonhomologous end joining.
Mu F; Liu T; Zheng H; Xie X; Lei T; He X; Du S; Tong R; Wang Y
Oncol Rep; 2018 Dec; 40(6):3663-3673. PubMed ID: 30272350
[TBL] [Abstract][Full Text] [Related]
79. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
80. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
